Abstract Objective To evaluate the effect of different protocols of intratympanic dexamethasone injection in pa• tients with unilateral sudden sensorineural hearing loss （SSNHL）who have failed to respond to typical medical treat• ment （including systemic steroid treatment） . Methods From January 2005 to January 2008, 71 patients who were diagnosed with unilateral SSNHL and failed typical medical treatment received intratympanic dexamethasone injec• tion. Four injection protocols were employed: injection of 0.3 ml dexamethasone （5 mg／ml）three times a week for 3 weeks for a total dose of 13.5 mg（Group I, n=16） ; injection of 0.6 ml (5 mg／ml）dexamethasone three times a week for 3 weeks for a total dose of 27 mg（Group II, n=18） ; injection at 0.3 ml （5 mg/ml）week for 6 weeks for a total dose of 9 mg（Group III, n=18） ; injection at 0.3 ml（5 mg／ml）／2 days for a total dose of 4.5 mg（Group IV n=19） . Hearing recovery was assessed by pure tone audiogram. Results The total effective rate was 37.5%, 38.89%, 33.33% and 36.84% for each treatment protocol, respectively, with no statistical difference between them（Ｐ > 0.05） . The re• sults suggest that a total dose of 4.5 mg（injected once a week for 3 weeks）is the most adequate protocol, and in• creasing dose or injection frequency yields no additional benefits. Conclusion Intratympanic dexamethasone signifi• cantly improves the prognosis of SSNHL. Small dose at low injection frequency is sufficient. Further multicenter stud• ies are needed to determine the standard treatment protocol.
Introduction
Sudden sensorineural hearing loss（SSNHL）is a syn• drome covering several heterogenous entities resulting from different pathogenetic mechanisms. Research has indicated that viral infection, microcirculation distur• bance, and autoimmune disorder could be possible key reasons for this hearing loss ［1-6］ . One generally accepted treatment for SSNHL is systemic steroids, which can be initiated prior to completion of studies such as magnetic resonance imaging（MRI） and autoantibodies testing. Steroids are believed to reduce inner ear inflammation and autoimmune response and to be beneficial for recov• ery of nerve function. Steroid receptors have been found in the inner ear and may explain why steroid therapy is effective. But for patients with diabetes, tumors, peptic ulcers, tuberculosis, hypertension and other systemic disorders, steroid therapy may not be appropriate. Intra• tympanic steroids injection is a new treatment choice for these patients, and may also offer alternatives for cases that have failed to respond to typical medicine treat• ments. The authors conducted a clinical study to deter• mine therapeutic effects of different intratympanic dexa• methasone injection protocols on sudden hearing loss, in an attempt to determine an appropriate protocol to im• prove our approach to SD.
Materials and methods
A prospective clinical study was conducted in 71 pa• tients diagnosed with unilateral SSNHL of unknown causes from January 2005 to January 2008, including （range 25-69 years） . All subjects satisfied the follow• ing conditions: (1) idiopathic unilateral sensorineural hearing loss, (2) no central nervous system disorders, (3) within 1-7 days after the onset of hearing loss, (4) previ• ously untreated, (5) normal hearing in the opposite ear for age, and (6) unresponsive to a 10 day course of typi• cal systemic medicine treatment including intravenous steroids, vasodilator, low-molecular-weight dextran, oral Ca 2 + channel blocker, hyperbaric oxygen. All pa• tients gave a complete clinical history, underwent physi• cal and audiologic examination, and received testing for syphilis and autoimmune antibodies. Magnetic reso• nance imaging （MRI）was negative in these patients. In• formed consent was obtained from each patients for par• ticipation in the study，and study protocols were ap• proved by the hospitals Ethics Committee.
The criteria of diagnosis and treatment effect classifi• cation for SSNHL published by Chinese Medical Associ• ation in 1997 ［7］ were adopted for this study. Pure-tone average（PTA）was calculated as the average of thresh• olds at 0.25, 0.5, 1, 2 and 4 kHz.
Severity of hearing loss was graded as: Mild: （26-40 dB） , Moderate: （41-55 dB） , Moderately severe:
（56-70 dB） , Severe:（71-90 dB）and Profound:（>90 dB） .
The extent of hearing recovery was reported as Com• plete Recovery（R）-PTA in normal limits or at pre-ill• ness level; Marked Recovery（MR）-PTA improve• ment ≥30 dB; Partial Recovery（PR）-PTA improve• ment 15 to 30 dB; And Unchanged（U）-PTA improve• ment≤ 15 dB Dexamethasone was delivered via a pressure equaliza• tion tube across the tympanic membrane, followed by fixed head position for 15 minutes to allow maximal ex• posure of the steroid to the round window.
A total of 71 cases were randomly selected to receive one of the four dexamethasone （5 mg／ml）dosing proto• cols: injection of 0.3 ml three times a week for 3 weeks for a total dose of 13.5 mg（Group Ⅰ, n=16） ; injection of 0.6 ml three times a week for 3 weeks for a total dose of 27 mg（Group Ⅱ, n=18） ; injection at 0.3 ml／week for 6 weeks for a total dose of 9 mg（Group IIⅡ, n=18） ; injection at 0.3 ml/2 days for a total of 3 injections and a total dose of 4.5 mg（Group Ⅳ n=19） . Patient profiles and therapeutic effects were compared among the 4 groups.
Statistical analysis： The mean age, average time from onset to treatment, and degree of hearing loss were analyzed by means of T-test. Treatment effects were analyzed by means of χ 2 test. P < 0.05 was considered significant. Table. 2 Therapeutic effect of four groups *：The effective rate was not statistically different between the four groups. （P > 0.05）
Results

Characteristics
The mean age, average time from onset to treatment, and degree of hearing loss were not statistically different between the four groups（P > 0.05） （table1） .
The effective rate was 37.5% , 38.89% , 33.33% and 36.84% , respectively, and not statistically different be• tween the four groups（P > 0.05） （table 2） .
Two patients declined further consultation. The total effective rate was 34.78%. Other than the expected tym• panic membrane perforation and nausea following injec• tion, there were no other serious unexpected adverse events. No increase in dizziness or tinnitus lasting lon• ger than 24 hours were observed after injections. Dis• cussion
It is generally acknowledged that the two important factors that influence the prognosis include the duration of hearing loss before seeking treatment, and the extent of hearing loss. In this study, patient age, interval from hearing loss onset to treatment and severity of hearing loss were not different between the four groups, making comparison of therapeutic effects relatively straightfor• ward.
Treatment of SSNHL remains controversial. Different approaches such as steroids, vasodilator, antiviral agents, diuretics, and low-salt diets have been suggest• ed. As a result of its anti-inflammatory and immunosup• pressive effects, high-dose systemic steroid therapy is currently the mainstay of treatment for SSNHL ［8-10］ . Re• current SSNHL is sensitive to transtympanic and system• ic steroid treatment Intratympanic steroid therapy is administered to the round window niche／membrane in the middle ear to target the inner ear. There is little systemic absorption, which makes it ideal for patients unable to take system• ic steroids. In addition, intratympanic steroid injection provides a higher concentration of steroid to the end or• gan， which may be most beneficial as primary therapy in patients unable to take systemic steroid therapy. The route of intratympanic delivery is usually via injection through the tympanic membrane, or drops instilled through pharyngotympanic tube. The former is a trau• matic mode, and tympanic membrane perforation, verti• go, nausea and pain after injection may be the expected adverse effects. The latter is relatively nontraumatic, but cannot be applied to patients with rhinopharyngitis or eustachian tube dysfunction. All patients are request• ed to keep their heads in a specified position for 15 to 20 minutes to allow maximal exposure of the steroid to the round window. Unfortunately, there is no consensus on a"standard"protocol for intratympanic steroid thera• py. In our study, the effective rate was not statistically different between the four tested treatment protocols, suggesting that different combination of dose, therapeu• tic frequency and duration do not influence treatment efficacy in SSNHL. A total dose of 4.5 mg (1.5 mg/injec• tion/week for 3 weeks) may be satisfactory.
An important factor of therapy is to initiate systemic steroids as early as possible. The highest rate of recov• ery has been found in patients who are started within 2 -4 weeks of onset of hearing loss.
Conclusions
